Silenor “Complete Response” Letter Hints At Efficacy Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Somaxon will meet with FDA to clarify what the issues for its insomnia agent are, but says an additional trial was not specifically requested; additional QT data is ready to submit.